Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | DAO | P14920 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 12/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942542 | 0.88 | ELANE (0.54) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL125345 | 0.85 | ELANE (0.62) | ELANE | |
| SCHEMBL124774 | 0.84 | RAB9A (0.54) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL941862 | 0.83 | ELANE (0.68) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL126653 | 0.83 | ELANE (0.68) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL3207971 | 0.83 | ELANE (0.68) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL3026330 | 0.81 | KMT2A (0.43) | RAB9AKDM4EELANEKMT2A | |
| Kojic Acid SCHEMBL3112595 | 0.79 | TYR (0.71) | DAOKDM4ETYRELANE | |
| SCHEMBL1686898 | 0.78 | DAO (0.58) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL3262761 | 0.78 | DAO (0.62) | RAB9ANPC1CYP1A2CYP2C19RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2428577-B1 | Preparation of tyrosinase-inhibiting hydroxybenzyl and hydroxypyranonemethyl esters | EASTMAN CHEM CO (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2428577-A1 | Preparation of tyrosinase-inhibiting hydroxybenzyl and hydroxypyranonemethyl esters | EASTMAN CHEMICAL COMPANY (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2155886-B1 | Cosmetic use of inhibitors of tyrosinase | EASTMAN CHEM CO (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110129430-A1 | HYDROXYBENZYL OR HYDROXYPYRANONEMETHYL ESTERS AS TYROSINASE INHIBITORS | EASTMAN CHEMICAL COMPANY (US) | 2011-06-02 | — | — | US | disclosed |
| US-20080306144-A1 | Hydroxybenzyl or hydroxypyranonemethyl esters as tyrosinase inhibitors | EASTMAN CHEMICAL COMPANY | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306144-A1 | Hydroxybenzyl or hydroxypyranonemethyl esters as tyrosinase inhibitors | TYR, TH, HAAO | RAB9A 3602/4885NPC1 3637/4885CYP1A2 597/4885 |
| US-20110129430-A1 | HYDROXYBENZYL OR HYDROXYPYRANONEMETHYL ESTERS AS TYROSINASE INHIBITORS | TYR, TH, HAAO | RAB9A 3602/4885NPC1 3637/4885CYP1A2 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.